New Market Study: "R&D Trends Melanoma - Drug Resistance Provides an Opportunity for Drug Developers""
The melanoma market has seen a large increase in developer attention following breakthroughs in treatment over the past year. Datamonitor has identified 108 drugs in the melanoma pipeline, with 7% in Phase III and 49% in Phase II trials. Early-stage developers are focusing on new targets in the MAPK pathway and immunomodulator targets such as PD-1 in an attempt to limit acquired resistance.
View full press release